AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16814257
Drug: Ethyl-eicosapentanoate (EPA)
RxNorm normalized name: Ethyl Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl-eicosapentanoate (EPA) 6 g/day
Trial: 8959788
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 micrograms four times daily)
Trial: 1493985
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg twice daily for three days
Trial: 30123250
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Treatment (AOT)
Trial: 31981294
Drug: Videogame Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videogame Observation Treatment (VOT)
Trial: 29174128
Drug: IUI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUI with ovarian stimulation (oral clomifene citrate 50-150 mg or oral letrozole 2.5-7.5 mg, days 2-6)
Trial: 25495953
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg/d) for 8 weeks
Trial: 23128104
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1-g capsules containing ≥840 mg n-3-PUFAs as ethyl esters) with preoperative loading of 10 g over 3 to 5 days followed by 2 g/d until hospital discharge or postoperative day 10.
Trial: 16858958
Drug: Oxcarbazepine 600
RxNorm normalized name: oxcarbazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 600 mg/d
Trial: 16858958
Drug: Oxcarbazepine 1200
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 1200 mg/d
Trial: 12456910
Drug: Pimecrolimus (Elidel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus (Elidel, SDZ ASM 981) cream 1%
Trial: 12456910
Drug: Pimecrolimus (Elidel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus (Elidel, SDZ ASM 981) cream 1% (after all patients switched at week 6)
Trial: 10878516
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin (400 mg every 12 hours)
Trial: 10878516
Drug: Intravenous imipenem-cilastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous imipenem-cilastatin (500 mg every 6 hours)
Trial: 20850296
Drug: Primary debulking
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary debulking surgery followed by chemotherapy
Trial: 16518708
Drug: Ciprofloxacin 1000
RxNorm normalized name: ciprofloxacin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1000 mg extended-release once-daily
Trial: 16518708
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg immediate-release twice-daily
Trial: 7798614
Drug: RA treatment
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RA treatment
Trial: 7798614
Drug: Anti-CD11c antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD11c antibody
Trial: 24781571
Drug: Subcutaneous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous saline injection to increase arterial depth from <2 mm to 2-4 mm
Trial: 24781571
Drug: Subcutaneous arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous arterial depth of 2-4 mm
Trial: 20227301
Drug: Sildenafil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil at 40 mg 3 times daily
Trial: 19326341
Drug: Double-dose antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose antioxidant supplement
Trial: 10197402
Drug: Standard ignoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ignoring treatment
Trial: 10197402
Drug: Graduated ignoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graduated ignoring treatment
Trial: 2132137
Drug: Bretylium 10
RxNorm normalized name: bretylium 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretylium 10 mg/kg
Trial: 358527
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride 10 mg
Trial: 358527
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride 20 mg
Trial: 28778550
Drug: Carbohydrate‐electrolyte‐protein solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte‐protein solution (CEP)
Trial: 26032216
Drug: Electrically induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrically induced muscle cramps (EIMCs) applied twice a week, 3x6 EIMCs of 5 seconds each
Trial: 22788697
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment applied to affected nails for 12 weeks
Trial: 21775557
Drug: Leucine-enriched essential
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-enriched essential amino acids (L-EAA) - 10 g EAA with 3.5 g leucine
Trial: 21775557
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids (EAA) - 10 g EAA with 1.87 g leucine
Trial: 8783540
Drug: Saline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline alone for maintenance of peripheral intravenous access devices
Trial: 8783540
Drug: Heparinized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized saline for maintenance of peripheral intravenous access devices
Trial: 6714820
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Orgotein and Corticoid)
Trial: 30064991
Drug: GM-CSF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (3 μg/kg/day), subcutaneous, once daily for 4 days
Trial: 24579075
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus acidophilus, Lactobacillus delbrueckii subsp. bulgaricus, and Bifidobacterium bifidus)
Trial: 22514718
Drug: Non-pharmaceutical interventions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical interventions (NPIs)
Trial: 18457471
Drug: Alfimeprase (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfimeprase (0.3 mg/kg)
Trial: 16076989
Drug: Green tea‐caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea‐caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine per day)
Trial: 12399201
Drug: 0.6 micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Trial: 12399201
Drug: 3.5 micro
RxNorm normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Trial: 12399201
Drug: 10 micro
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Trial: 12399201
Drug: 20 micro
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Trial: 7746026
Drug: Eferox 100
RxNorm normalized name: Aloe ferox leaf
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eferox 100 tablets (100 micrograms levothyroxine‐Na)
Trial: 7746026
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (100 micrograms levothyroxine‐Na)
Trial: 2646206
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg twice a day
Trial: 1215859
Drug: tetracycline HCl
RxNorm normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline HCl 1 g
Trial: 1215859
Drug: tetracycline HCl
RxNorm normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline HCl + terpenes 100 mg
Trial: 1215859
Drug: minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minocycline 200 mg
Trial: 1215859
Drug: cotrimoxazole (sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cotrimoxazole (sulfamethoxazole 1.6 g + trimethoprim 320 mg)
Trial: 31763286
Drug: Oral Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ivermectin (6 mg each, two doses 24 hours apart)
Trial: 29333775
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 μg·kg⁻¹ bolus, saline diluted to 10 mL, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Trial: 29333775
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (10 mL bolus, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Trial: 15498605
Drug: MSL-109 15
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109 15 mg
Trial: 15498605
Drug: MSL-109 60
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109 60 mg
Trial: 11430552
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG1)
Trial: 11430552
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG2)
Trial: 11430552
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin 20% 1.75 ml/kg body weight (Group ALB)
Trial: 11430552
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 6% 5.25 ml/kg body weight (Group HAES)
Trial: 11430552
Drug: Polygelatine 3.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polygelatine 3.5% 7.0 ml/kg body weight (Group HAEM)
Trial: 7818586
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice a day for 4 weeks
Trial: 3337412
Drug: One-dose activated
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose activated charcoal (50 g)
Trial: 3337412
Drug: Two-dose activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose activated charcoal (50 g)
Trial: 3337412
Drug: Three-dose activated
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose activated charcoal (50 g)
Trial: 21173495
Drug: Waon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waon therapy (daily for 4 weeks)
Trial: 21173495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard optimal medications for CHF)
Trial: 15070944
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss with PEG-OB treatment
Trial: 15070944
Drug: PEG-OB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-OB treatment
Trial: 9492731
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg intravenous infusion before operation and again 8 hours later)
Trial: 3128132
Drug: Nitroglycerin infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion, 1 to 2 micrograms.kg‐1.min‐1
Trial: 3128132
Drug: No nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nitroglycerin infusion
Trial: 22488751
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment with rectal balloon training and pelvic floor muscle training
Trial: 22488751
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of constipating medication
Trial: 18633251
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 6.0 day 1 and paclitaxel 70 mg/m2 day 1, 8, 15 every 4 weeks followed by gemcitabine 1.0 g/m2 day 1, 8, 15 every 4 weeks (Group CP)
Trial: 18633251
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 2.0 and gemcitabine 0.8 g/m2 day 1, 8 every 3 weeks followed by docetaxel 60 mg/m2 day 1, 8 every 3 weeks (Group CG)
Trial: 10224335
Drug: Rifametane (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifametane (300 mg single oral dose)
Trial: 10224335
Drug: Rifampicin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (300 mg single oral dose)
Trial: 12202968
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg/day)
Trial: 6742536
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg for <65 years; 0.085 mg/kg for ≥65 years)
Trial: 6742536
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg/kg for <65 years; 0.15 mg/kg for ≥65 years)
Trial: 26083427
Drug: Lidocaine (2%)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (2%) via intravenous bolus (1.5 mg/kg) followed by infusion at 2 mg/kg/h until the end of surgery
Trial: 24291444
Drug: Active music
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active music therapy control
Trial: 17666280
Drug: Alternative non-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative non-heparin anticoagulants (danaparoid, lepirudin, argatroban)
Trial: 16135578
Drug: Drospirenone 3
RxNorm normalized name: drospirenone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 3 mg and Ethinyl Estradiol 20 microg (24/4 regimen)
Trial: 11906496
Drug: Clinafloxacin monotherapy
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinafloxacin monotherapy (200 mg every 12 h)
Trial: 11906496
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g every 8 h) plus Amikacin (15 mg/kg per day)
Trial: 2405347
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro antibody production of HIV‐specific IgG
Trial: 25872505
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help program (deprexis®) with 12 weekly tasks during inpatient treatment
Trial: 25872505
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to an online platform with weekly updated information on depression
Trial: 19728564
Drug: Compounds 1-7
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compounds 1-7
Trial: 19728564
Drug: Compounds 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounds 1, 3, 4, 5, 6, and 7
Trial: 19728564
Drug: Compound 5
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound 5
Trial: 9032106
Drug: Nisoldipine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20-40 mg once daily)
Trial: 21780182
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (0.8 mg folic acid, 0.5 mg vitamin B12, 20 mg vitamin B6)
Trial: 12358304
Drug: Topical instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical instillation of non-selective beta-adrenoceptor antagonist (timolol)
Trial: 12358304
Drug: Topical instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical instillation of selective beta-adrenoceptor antagonist (betaxolol)
Trial: 9103279
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of salicylates
Trial: 15926987
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit
Trial: 10148570
Drug: Non heparin-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non heparin-coated circuit with systemic heparin
Trial: 29124826
Drug: Sequential delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential delivery of HE intervention
Trial: 29124826
Drug: Sequential nudge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential nudge intervention delivery
Trial: 20456841
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (Group A)
Trial: 16100296
Drug: Crushed tablets
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablets mixed in 240 mL nutritional supplement drink followed by 120 mL water
Trial: 16100296
Drug: Whole tablets
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablets swallowed with 240 mL water
Trial: 26811090
Drug: Saffron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (300 mg/day for 10 days)
Trial: 24535415
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) at dosages of 1.2, 2.4, and 4.8 g/day for 6 weeks
Trial: 24535415
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) at high dosage (4.8 g/day)
Trial: 9495423
Drug: Dextromethorphan 45
RxNorm normalized name: BUPROPION 105MG/DEXTROMETHORPHAN 45MG TAB,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 45 mg
Trial: 17110451
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K supplementation (150 mug daily for 6 months)
Trial: 12468788
Drug: Gait trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gait trainer therapy (2 weeks)
Trial: 12468788
Drug: Treadmill therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treadmill therapy (2 weeks)
Trial: 8605522
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (rBS/WC)
Trial: 2686256
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg/day) added to nitrates, beta-blockers, and calcium entry blockers
Trial: 2686256
Drug: Nitrates, beta-blockers,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates, beta-blockers, and calcium entry blockers (without aspirin)
Trial: 4610853
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment within the first 24 hours of thermal injuries
Trial: 25773378
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg)
Trial: 20370312
Drug: BIT (Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIT (Behavioral Internet Treatment)
Trial: 15999906
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs (sedative and non-sedative neuroleptics, antidepressants, tranquilizers, hypnotics, psychostimulants, cognition-enhancing drugs)
Trial: 12113585
Drug: PSAV cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSAV cutoff of 0.75 ng/mL/year
Trial: 12113585
Drug: PSAV cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSAV cutoff of 0.10 ng/mL/year
Trial: 2188479
Drug: mianserin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (up to 90 mg per day)
Trial: 2188479
Drug: maprotiline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline (up to 150 mg per day)
Trial: 6117728
Drug: Drugs to
RxNorm normalized name: soap/herbal drugs TOPICAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs to induce initial remission
Trial: 24817242
Drug: Rhinotopic protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinotopic protocol consisting of twice-daily saline rinses, nebulized corticosteroid, and nebulized antibiotic for 6 weeks, followed by once-weekly endoscopic sinus debridement and topical intrasinus installation of corticosteroid and antibiotic.
Trial: 22284902
Drug: HM30181 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181 180 mg single-dose